Sun Pharma.Inds.

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 02-Jul, Sun Pharmaceutical Industries Ltd's stock price is rising at 1,871.55, with a year-to-date increase of 8.83% and a return of 11.40% over the past year, outperforming the Sensex. Despite a decline in investor participation, strong fundamentals and positive trends support the stock's upward movement.

As of 02-Jul, Sun Pharmaceutical Industries Ltd's stock price is rising, currently at 1,871.55, reflecting a change of 5.6 (0.3%) upward. The stock has shown consistent performance over various periods, with a year-to-date increase of 8.83% compared to a decline of 9.06% in the benchmark Sensex. Over the past year, the stock has generated a return of 11.40%, significantly outperforming the Sensex, which has fallen by 7.08%.<BR><BR>The stock's recent performance is also supported by its trading above all key moving averages, indicating a positive trend. Furthermore, the stock has been gaining for the last two days, with a return of 0.44% during this period. Despite a slight underperformance against its sector today, the overall long-term fundamentals remain strong, characterized by healthy growth in net sales and operating profit, alongside a net-debt-free status.<BR><BR>Additionally, the company benefits from high institutional holdings at 37.04%, suggesting confidence from larger investors who typically have more resources to analyze the company's fundamentals. Sun Pharmaceutical Industries Ltd is also recognized as one of the highest-rated companies by MarketsMojo, further bolstering investor confidence.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 37.16% against the five-day average. This could indicate a potential risk if the trend continues. Nonetheless, the overall positive factors, including strong fundamentals and consistent returns, contribute to the stock's rising price.

Which are the latest news on Sun Pharma.Inds.?

What does Sun Pharma.Inds. do?

Sun Pharmaceutical Industries Ltd is a leading global specialty generic pharmaceutical company, incorporated in 1993, and is the largest Indian pharmaceutical firm in the US. As of March 2026, it reported net sales of ₹14,612 Cr and a net profit of ₹2,714 Cr, with a market cap of ₹426,122 Cr.

Overview:<BR>Sun Pharmaceutical Industries Ltd is a large-cap company in the Pharmaceuticals & Biotechnology industry, recognized as the fourth largest global specialty generic company.<BR><BR>History:<BR>Sun Pharmaceutical Industries Ltd was incorporated in 1993 and has since grown to become the largest Indian pharmaceutical company in the US. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 14,612 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2,714 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 426,122 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 34.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.93% <BR>Debt-Equity: -0.33 <BR>Return on Equity: 14.92% <BR>Price to Book: 5.11<BR><BR>Contact Details:<BR>Address: Sun Pharma Advanced Res.Centre, Tandalja Vadodara Gujarat : 390020 <BR>Tel: 91-265-6615500 <BR>Email: secretarial@sunpharma.com <BR>Website: http://www.sunpharma.com

How big is Sun Pharma.Inds.?

As of 10th June, Sun Pharmaceutical Industries Ltd has a market capitalization of 426,122.00 Cr, with recent net sales of 58,462.04 Cr and net profit of 11,479.42 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Sun Pharmaceutical Industries Ltd has a market capitalization of 426,122.00 Cr, classified as Large Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 58,462.04 Cr, while the sum of Net Profit for the same period is 11,479.42 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 72,218.02 Cr, and Total Assets amount to 87,693.03 Cr.

Who are in the management team of Sun Pharma.Inds.?

The management team of Sun Pharma.Inds. includes key members such as Dilip S Shanghvi (Managing Director), Sudhir V Valia (Non-Executive Director), and several independent directors like Pawan Goenka and Rama Bijapurkar, among others, who guide the company's strategic direction and governance.

The management team of Sun Pharma.Inds. includes the following key members:<BR><BR>1. **Dilip S Shanghvi** - Managing Director<BR>2. **Sudhir V Valia** - Non-Executive & Non-Independent Director<BR>3. **Sailesh T Desai** - Whole-time Director<BR>4. **Gautam Doshi** - Non-Executive & Independent Director<BR>5. **Pawan Goenka** - Lead Independent Director<BR>6. **Rama Bijapurkar** - Independent Director<BR>7. **Anoop Deshpande** - Company Secretary & Compliance Officer<BR>8. **Sanjay K Asher** - Independent Director<BR>9. **Rolf Hoffmann** - Independent Director<BR>10. **Aalok Shanghvi** - Whole-time Director<BR><BR>This team plays a crucial role in the strategic direction and governance of the company.

Who are the peers of the Sun Pharma.Inds.?

Sun Pharma.Inds. peers include Divi's Lab., Torrent Pharma, Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, and Laurus Labs. Key insights show excellent management and capital structures for several peers, with Laurus Labs leading in 1-year returns at 106.68%, while Sun Pharma.Inds. has a 1-year return of 5.81%.

Peers: The peers of Sun Pharma.Inds. are Divi's Lab., Torrent Pharma, Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Divi's Lab., Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, and Laurus Labs, while Average management risk is found at Aurobindo Pharma and Biocon. Growth is excellent for Sun Pharma.Inds., Zydus Lifesci., Lupin, Mankind Pharma, while below average growth is noted for Divi's Lab., Cipla, Aurobindo Pharma, Laurus Labs, and Biocon, with the rest showing average or good growth. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Zydus Lifesci., Dr Reddy's Labs, Mankind Pharma, and Aurobindo Pharma, while good capital structure is noted for Torrent Pharma and Lupin, and average capital structure is found at Laurus Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Laurus Labs at 106.68%, while the lowest is Cipla at -8.87%. Sun Pharma.Inds. has a 1-year return of 5.81%, which is higher than Cipla's but lower than Laurus Labs'. Additionally, Cipla, Dr Reddy's Labs, and Aurobindo Pharma have negative six-month returns.

Should I buy, sell or hold Sun Pharmaceutical Industries Ltd?

Are Sun Pharmaceutical Industries Ltd latest results good or bad?

Sun Pharmaceutical Industries Ltd's latest results show strong year-on-year revenue and profit growth, but a decline in sequential sales and operating margins raises concerns about near-term profitability and cost management. Investors should monitor these trends closely.

Sun Pharmaceutical Industries Ltd's latest results present a mixed picture. On one hand, the company achieved a notable year-on-year revenue growth of 12.76%, with net sales reaching ₹14,611.79 crores in Q4 FY26. Additionally, net profit for the quarter increased by 26.24% year-on-year to ₹2,714 crores. This demonstrates strong demand and effective volume growth driven by new product launches.<BR><BR>However, there are significant concerns regarding sequential performance. The net sales declined by 5.86% compared to the previous quarter, and the operating margins contracted sharply to 27.16%, down from 31.99% in Q3 FY26. This decline in margins indicates pricing pressures and cost inflation challenges that the company is currently facing. Furthermore, net profit fell by 19.44% quarter-on-quarter, highlighting operational leverage issues.<BR><BR>Overall, while Sun Pharma shows resilience in its year-on-year growth, the sequential decline in sales and margins raises questions about its near-term profitability and cost management. Investors may need to monitor these trends closely to assess the company's ongoing performance and outlook.

When is the next results date for Sun Pharmaceutical Industries Ltd?

The next results date for Sun Pharmaceutical Industries Ltd is 22 May 2026.

The next results date for Sun Pharmaceutical Industries Ltd is scheduled for 22 May 2026.

Has Sun Pharmaceutical Industries Ltd declared dividend?

Yes, Sun Pharmaceutical Industries Ltd has declared a dividend of 1100% (₹5.5 per share), with an ex-date of February 5, 2026. While recent short-term returns have been negative, the company has shown strong growth over longer periods.

Sun Pharmaceutical Industries Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1100%<BR>- Amount per share: 5.5<BR>- Ex-date: 05 Feb 26<BR><BR>Dividend Yield: 1%<BR><BR>Total Returns by Period:<BR>In the 3-month period, the price return was -5.48%, the dividend return was 0.65%, resulting in a total return of -4.83%.<BR><BR>In the 6-month period, the price return was -7.19%, the dividend return was 0.67%, leading to a total return of -6.52%.<BR><BR>For the 1-year period, the price return was -7.74%, the dividend return was 0.95%, culminating in a total return of -6.79%.<BR><BR>Over the 2-year period, the price return was 17.4%, the dividend return was 2.09%, resulting in a total return of 19.49%.<BR><BR>In the 3-year period, the price return was 53.22%, the dividend return was 4.52%, leading to a total return of 57.74%.<BR><BR>For the 4-year period, the price return was 94.64%, the dividend return was 6.50%, culminating in a total return of 101.14%.<BR><BR>In the 5-year period, the price return was 174.57%, the dividend return was 10.59%, resulting in a total return of 185.16%.<BR><BR>Overall, Sun Pharmaceutical Industries Ltd has declared a significant dividend, and while recent short-term returns have been negative, the longer-term returns indicate strong growth and positive performance over the years.

Is Sun Pharma.Inds. technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish due to a bullish MACD and daily moving average, but caution is warranted from mixed signals in longer-term indicators.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the monthly MACD and KST are mildly bearish, indicating some caution. The Bollinger Bands show a mildly bullish trend on the weekly, while the Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. Overall, the strength of the bullish sentiment is tempered by mixed signals in the longer-term indicators.

How has been the historical performance of Sun Pharma.Inds.?

Sun Pharma.Inds. has shown consistent growth from March 2019 to March 2025, with net sales increasing from 29,065.91 Cr to 52,578.44 Cr, and profit after tax rising from 3,209.32 Cr to 10,980.10 Cr. The company has also improved its operating profit margin and cash flow, indicating strong financial health.

Answer:<BR>The historical performance of Sun Pharma.Inds. shows a consistent growth trajectory in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Sun Pharma.Inds. has demonstrated significant growth in net sales, increasing from 29,065.91 Cr in March 2019 to 52,578.44 Cr in March 2025. Total operating income has followed a similar upward trend, reaching 52,578.44 Cr in March 2025, up from 29,065.91 Cr in March 2019. The company's operating profit (PBDIT) has also improved markedly, rising from 7,333.08 Cr in March 2019 to 17,236.73 Cr in March 2025, reflecting a robust operating profit margin of 29.35% in the latest fiscal year. Profit before tax has surged to 13,752.13 Cr in March 2025, compared to 3,810.20 Cr in March 2019, while profit after tax reached 10,980.10 Cr, up from 3,209.32 Cr in March 2019. The company's total assets have increased from 65,077.17 Cr in March 2020 to 87,693.03 Cr in March 2025, indicating strong asset growth. Total liabilities have also risen, from 65,077.17 Cr in March 2020 to 87,693.03 Cr in March 2025, with total debt decreasing from 7,578.30 Cr in March 2020 to 1,869.63 Cr in March 2025. Cash flow from operating activities has improved significantly, reaching 14,072.00 Cr in March 2025, compared to 6,554.00 Cr in March 2020, contributing to a closing cash and cash equivalent of 10,268.00 Cr in March 2025. Overall, Sun Pharma.Inds. has shown a strong upward trend in revenue, profitability, and cash flow, positioning itself favorably in the market.

Who are the top shareholders of the Sun Pharma.Inds.?

The top shareholders of Sun Pharma.Inds. include Shanghvi Finance Private Limited (40.3%), institutional investors like mutual funds (12.21%) and FIIs (17.96%), with ICICI Prudential Value Discovery Fund as the largest public shareholder (3.35%), while individual investors hold 5.42%. This indicates strong support from both promoters and institutional investors.

The top shareholders of Sun Pharma.Inds. include a mix of promoters, institutional investors, and individual shareholders. The majority of the shares are held by promoters, with Shanghvi Finance Private Limited being the largest promoter, holding 40.3% of the company. <BR><BR>In terms of institutional holdings, mutual funds account for 12.21% of the shares, with 44 different schemes involved. Foreign Institutional Investors (FIIs) hold 17.96% of the company, represented by 1206 FIIs. The highest public shareholder is ICICI Prudential Value Discovery Fund, which holds 3.35%. Additionally, individual investors collectively hold 5.42% of the shares. <BR><BR>This diverse shareholder structure reflects a strong backing from both promoters and institutional investors.

Is Sun Pharma.Inds. overvalued or undervalued?

As of May 23, 2025, Sun Pharmaceutical Industries Ltd. is considered overvalued with a PE ratio of 35.25 and a valuation grade of expensive, despite strong fundamentals, as it has underperformed the Sensex with a year-to-date return of -10.51%.

As of 23 May 2025, the valuation grade for Sun Pharmaceutical Industries Ltd. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still reflecting a high valuation. The company is currently considered overvalued, with a PE ratio of 35.25, a Price to Book Value of 5.58, and an EV to EBITDA of 24.91. <BR><BR>In comparison to peers, Sun Pharma's PE ratio is higher than that of its competitor, which has a PE of approximately 30. This suggests that Sun Pharma is priced at a premium relative to its industry peers. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -10.51% compared to the Sensex's 5.58%. Overall, while there are strong fundamentals such as a ROCE of 25.60% and a ROE of 15.83%, the current valuation metrics indicate that Sun Pharma is overvalued in the market.

What is the bonus history of the Sun Pharma.Inds.?

Sun Pharmaceutical Industries Ltd issued a 1:1 bonus on July 29, 2013, with a record date of July 30, 2013, allowing shareholders to double their holdings.

Sun Pharmaceutical Industries Ltd has a bonus history that includes a 1:1 bonus issue announced on July 29, 2013. The record date for this bonus was July 30, 2013. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about Sun Pharma or need further details, feel free to ask!